Lineage Cell Therapeutics Inc (LCTX) Stock Price, Quote & News

Company Profile

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 442 287 8990

Website: www.lineagecell.com

Address:

2173 Salk Avenue, Suite 200, Carlsbad, United States

Logic102 Aug. 24 at 3:50 PM

$LCTX Nice to see some green on a tough Market Day. Probably meaningless, but I'll take it with most of my small names getting slaughtered in recent days.

0 · Reply

1900jetpack Aug. 24 at 9:34 AM

$LCTX 2 more years trust the process

0 · Reply

Goodhealth Aug. 24 at 9:03 AM

$LCTX A possible positive development. ChatGpt: "The most important news from the earnings call If I had to reduce the entire conversation to five points, I would choose: 🥇 1. Roche is actively working on delivery That is the most important clinical information. 🥈 2. 17 GAlette sites That makes upcoming data more informative. 🥉 3. Commercial manufacturing is already part of the Roche/LCTX collaboration Interesting strategic signal. 4. Cash by Q3 2028 LCTX can wait for clinical catalysts. 5. AlloSCOPE starts to demonstrate broader platform value COR1 + ReSonance + ILT1." https://www.businesswire.com/news/home/20260806053201/en/Lineage-Cell-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update?feedref=Zd8jjkgYuzBwDixoAdXmJgT1albrG1Eq4mAeVP39211KIY8dqRJOTu36zg5ojSWrevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxYjwPpKemorG67JEVtPrh6fM-qD99V7nLhHRG_XnYInrw%3D%3D

0 · Reply

Ablidy Aug. 23 at 7:59 PM

$LCTX big editorial in Nature On stem cells , p539, vol656 ,20 August 2026 with clinical trials well under way , public trust must be retained ….many of the trials will report results over the next 5 years ….with manufacturing a must and paradigm instructions for the immune operational manuals now a hot topic of rebooting alpha DC1 cells for anti aging process with two subsets , cancer and autoimmune control by IRF8 gen and cytokines IZl-12p70 for the lock with Stat3 caused by senescence ( zomibie and ghost cells) that pull to tolerance…..

0 · Reply

alphadog10 Aug. 23 at 5:39 PM

$LCTX Adding 100% to short position first thing monday

1 · Reply

JP73 Aug. 23 at 5:30 PM

$LCTX ...FDA commissioner....Who is closing their position based on this nominee? reducing 25%? reducing 50%?......Silence implies no reduction or closure.

1 · Reply

alphadog10 Aug. 23 at 1:21 PM

$LCTX Long Heidi Overton SHORT Lame duck culley

0 · Reply

JohnPDaly Aug. 23 at 11:51 AM

$LCTX https://ipscell.com/2026/08/weekly-reads-heidi-overton-fda-commish-nominee-nasa-stem-cells-aged-brain-organoids-cautious-nature-ips-cell-editorial/

3 · Reply

JohnPDaly Aug. 23 at 11:50 AM

$LCTX Overton has been a leader at the America First Policy Institute, which opposes human embryonic stem cell research. She also has played roles in disrupting vaccination policy.-The Niche

1 · Reply

Ablidy Aug. 23 at 10:36 AM

$LCTX

0 · Reply

Lineage Cell Therapeutics Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 17 days ago

Lineage Cell Therapeutics Earnings release: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 17 days ago

Lineage Cell Therapeutics Quarterly report: Q2 2026

2026-08-06T20:17:34.000Z - 17 days ago

Lineage Cell Therapeutics reports Q2 EPS (3c), consensus (3c)

Aug 6, 2026, 4:01 PM EDT - 17 days ago

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Jul 30, 2026, 8:00 AM EDT - 25 days ago

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Jul 13, 2026, 4:30 PM EDT - 5 weeks ago

Lineage Cell Therapeutics Transcript: Study update

Jul 13, 2026, 4:30 PM EDT - 5 weeks ago

Lineage Cell Therapeutics Press release: Study update

2026-07-13T12:05:45.000Z - 6 weeks ago

Lineage Cell Therapeutics provides update on COR1 program

Jul 13, 2026, 8:00 AM EDT - 6 weeks ago

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

Jul 6, 2026, 8:00 AM EDT - 7 weeks ago

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

2026-05-12T22:11:23.000Z - 3 months ago

Lineage Cell Therapeutics reports Q1 EPS (3c), consensus (2c)

May 12, 2026, 4:30 PM EDT - 3 months ago

Lineage Cell Therapeutics Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

Lineage Cell Therapeutics Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

Lineage Cell Therapeutics Quarterly report: Q1 2026

May 12, 2026, 4:01 PM EDT - 3 months ago

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 7:00 AM EDT - 3 months ago

Lineage Cell Therapeutics Slides: Corporate presentation

May 5, 2026, 8:00 AM EDT - 3 months ago

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

2026-05-04T13:24:29.000Z - 4 months ago

Lineage Cell announces 36-month results from Phase 1/2a study of RG6501

May 4, 2026, 8:00 AM EDT - 4 months ago

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Lineage Cell Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Lineage Cell Therapeutics Proxy statement: Proxy filing

2026-04-28T11:14:03.000Z - 4 months ago

Lineage Cell Therapeutics initiated with a Buy at Canaccord

2026-04-13T12:26:16.000Z - 4 months ago

Lineage Cell Therapeutics announces formation of Scientific Advisory Board

Apr 13, 2026, 8:00 AM EDT - 4 months ago

Lineage Announces Formation of Scientific Advisory Board

2026-04-08T20:56:34.000Z - 4 months ago

Lineage Cell Therapeutics management to meet with Craig-Hallum

2026-03-25T12:16:37.000Z - 5 months ago

Lineage Cell Therapeutics price target raised to $4 from $3 at B. Riley

Mar 25, 2026, 7:00 AM EDT - 5 months ago

Lineage Cell Therapeutics Slides: Corporate presentation

Mar 24, 2026, 8:00 AM EDT - 5 months ago

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

Mar 11, 2026, 8:00 AM EDT - 5 months ago

Lineage Cell Therapeutics Registration statement: Registration Filing

Mar 5, 2026, 4:30 PM EST - 6 months ago

Lineage Cell Therapeutics Earnings Call Transcript: Q4 2025

Mar 5, 2026, 4:30 PM EST - 6 months ago

Lineage Cell Therapeutics Annual report: Q4 2025

Mar 5, 2026, 4:30 PM EST - 6 months ago

Lineage Cell Therapeutics Earnings release: Q4 2025

2026-03-05T21:11:09.000Z - 6 months ago

Lineage Cell Therapeutics reports Q4 EPS 0c vs (2c) last year

Mar 5, 2026, 4:01 PM EST - 6 months ago

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 8:00 AM EST - 6 months ago

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

2026-02-20T14:15:55.000Z - 6 months ago

Lineage Cell Therapeutics management to meet with B, Riley

2026-01-06T13:15:39.000Z - 8 months ago

Lineage Cell Therapeutics receives iPSC line from Factor Bioscience

Jan 6, 2026, 8:00 AM EST - 8 months ago

Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

Jan 5, 2026, 8:00 AM EST - 8 months ago

Lineage Cell Therapeutics Issues Letter to Stockholders

2025-11-24T17:20:20.000Z - 9 months ago

Lineage Cell says first OpRegen development milestone under Roche pact achieved

2025-11-24T17:15:15.000Z - 9 months ago

Lineage Cell’s OpRegen shows evidence of progress, says H.C. Wainwright

Nov 6, 2025, 4:30 PM EST - 10 months ago

Lineage Cell Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 10 months ago

Lineage Cell Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 10 months ago

Lineage Cell Therapeutics Earnings release: Q3 2025

2025-11-06T21:12:07.000Z - 10 months ago

Lineage Cell Therapeutics reports Q3 EPS (13c), consensus (3c)

Nov 6, 2025, 4:01 PM EST - 10 months ago

Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 30, 2025, 8:00 AM EDT - 10 months ago

Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Sep 8, 2025, 11:30 AM EDT - 1 year ago

Lineage Cell Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

2025-09-08T12:10:26.000Z - 1 year ago

Lineage Cell Therapeutics initiates new islet cell transplant program

Sep 8, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes

Sep 2, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Present at September 2025 Investor Conferences

2025-08-26T12:05:19.000Z - 1 year ago

Lineage Cell Therapeutics enters research pact with William Demant Invest

Aug 26, 2025, 8:00 AM EDT - 1 year ago

Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 4:01 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

Jun 23, 2025, 7:00 AM EDT - 1 year ago

OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics Proxy statement: Proxy Filing

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

May 20, 2025, 2:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 13, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Earnings release: Q1 2025

May 13, 2025, 4:01 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 8:00 AM EDT - 1 year ago

RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

Mar 10, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Earnings Call Transcript: Q4 2024

Mar 10, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Annual report: Q4 2024

Mar 10, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Earnings release: Q4 2024

Mar 10, 2025, 4:05 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 5, 2025, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

Feb 11, 2025, 12:40 PM EST - 1 year ago

Lineage Cell Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 12:40 PM EST - 1 year ago

Lineage Cell Therapeutics Slides: FY 2025

Feb 11, 2025, 8:00 AM EST - 1 year ago

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

Feb 4, 2025, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

Jan 27, 2025, 4:05 PM EST - 1 year ago

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

Dec 9, 2024, 7:00 AM EST - 1 year ago

Lineage Cell Therapeutics Proxy statement: Proxy Filing

Nov 29, 2024, 7:00 AM EST - 1 year ago

Lineage Cell Therapeutics Proxy statement: Proxy Filing

Nov 21, 2024, 5:00 PM EST - 1 year ago

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

Nov 20, 2024, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

Nov 14, 2024, 4:30 PM EST - 1 year ago

Lineage Cell Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Lineage Cell Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Lineage Cell Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 4:01 PM EST - 1 year ago

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

Oct 14, 2024, 8:00 AM EDT - 2 years ago

Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

Sep 25, 2024, 8:00 AM EDT - 2 years ago

OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

Sep 18, 2024, 8:00 AM EDT - 2 years ago

Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop

Aug 15, 2024, 7:00 AM EDT - 2 years ago

Lineage Cell Therapeutics Transcript: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Lineage Cell Therapeutics Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Lineage Cell Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Lineage Cell Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 4:05 PM EDT - 2 years ago

Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 1, 2024, 8:00 AM EDT - 2 years ago

Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Jul 2, 2024, 8:00 AM EDT - 2 years ago

Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index

May 30, 2024, 8:00 AM EDT - 2 years ago

Lineage to Present at 2024 BIO International Convention

May 21, 2024, 8:00 AM EDT - 2 years ago

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

May 9, 2024, 4:30 PM EDT - 2 years ago

Lineage Cell Therapeutics Earnings Call Transcript: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Lineage Cell Therapeutics Quarterly report: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Lineage Cell Therapeutics Earnings release: Q1 2024

May 9, 2024, 4:01 PM EDT - 2 years ago

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 8:00 AM EDT - 2 years ago

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

May 2, 2024, 8:00 AM EDT - 2 years ago

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Logic102 Aug. 24 at 3:50 PM

$LCTX Nice to see some green on a tough Market Day. Probably meaningless, but I'll take it with most of my small names getting slaughtered in recent days.

0 · Reply

1900jetpack Aug. 24 at 9:34 AM

$LCTX 2 more years trust the process

0 · Reply

Goodhealth Aug. 24 at 9:03 AM

0 · Reply

Ablidy Aug. 23 at 7:59 PM

0 · Reply

alphadog10 Aug. 23 at 5:39 PM

$LCTX Adding 100% to short position first thing monday

1 · Reply

JP73 Aug. 23 at 5:30 PM

$LCTX ...FDA commissioner....Who is closing their position based on this nominee? reducing 25%? reducing 50%?......Silence implies no reduction or closure.

1 · Reply

alphadog10 Aug. 23 at 1:21 PM

$LCTX Long Heidi Overton SHORT Lame duck culley

0 · Reply

JohnPDaly Aug. 23 at 11:51 AM

$LCTX https://ipscell.com/2026/08/weekly-reads-heidi-overton-fda-commish-nominee-nasa-stem-cells-aged-brain-organoids-cautious-nature-ips-cell-editorial/

3 · Reply

JohnPDaly Aug. 23 at 11:50 AM

$LCTX Overton has been a leader at the America First Policy Institute, which opposes human embryonic stem cell research. She also has played roles in disrupting vaccination policy.-The Niche

1 · Reply

Ablidy Aug. 23 at 10:36 AM

$LCTX

0 · Reply

Ablidy Aug. 23 at 10:35 AM

$LCTX

1 · Reply

Ablidy Aug. 23 at 10:33 AM

$LCTX

0 · Reply

Ablidy Aug. 23 at 10:31 AM

$LCTX

1 · Reply

RUNNINWILD Aug. 23 at 1:37 AM

$LCTX https://www.yahoo.com/news/science/articles/billionaire-home-depot-cofounder-bernie-070000773.html

1 · Reply

Trak2 Aug. 22 at 5:45 PM

$LCTX CRAZY, conservative based research, I don’t like the sound of that!

1 · Reply

JohnPDaly Aug. 22 at 4:49 PM

$LCTX https://x.com/factpostnews/status/2090834622372262094?s=12

6 · Reply

imatisse Aug. 22 at 4:38 PM

$RHHBY De nombreux indices “tea/leaf” laissent désormais penser que #Roche #Genentech considère sérieusement #OpRegen $LCTX ($50,8m cash) comme un produit potentiellement commercialisable, y compris au niveau de la distribution + fabrication! #GAlette @17sites #AlloSCOPE ❤️

0 · Reply

Goodhealth Aug. 22 at 3:38 PM

$LCTX ChatGpt: I can now document at least two recent Genentech-owned patent families that are very close to the problem GAlette is trying to solve: Patent Priority Owner What it does Relevance to OpReGen Ocular cannula guide, applicator & marking instrument — WO2025072590 09/29/2023 Genentech Positioning/steering of cannula for subretinal delivery Torque ring for subretinal injection device — WO2025207699 03/27/2024 Genentech Control of subretinal injection instrument Dual-curved needle — WO2024052733 09/06/2022 Gyroscope → Genentech Precise subretinal delivery Dose dock for syringe — WO2024150069 01/13/2023 Gyroscope → Genentech Dose/Syringe Control Older Subretinal Delivery Patents 2014–2021 Gyroscope → Genentech Basic Delivery Platform The patent database specifically shows that WO2025072590 has Genentech as both the original and current assignee, with priority September 29, 2023. And WO2025207699 appears as a Genentech family with priority March 27, 2024.

2 · Reply

Goodhealth Aug. 22 at 3:14 PM

$LCTX The two devices have been identified Lineage CEO Brian Culley explained in Q1 2025 that Genentech planned to test two proprietary devices in GAlette: Dual lumen Transvitreal Subretinal Injector (TVSI) Next-generation Orbit SDS (Subretinal Delivery System) He also explained exactly what they were supposed to solve. And Roche itself later presented both technologies at Roche Pharma Day 2025 as "Advanced subretinal delivery devices" under the OpRegen program.

1 · Reply

Logic102 Aug. 22 at 3:02 PM

$LCTX It's a great sign that Roche/Genentech is now working with both the EMA and the FDA regarding OpRegen. Logically, real progress with Regulators will not be made until a move to P3. The FDA, unfortunately, is a mess currently, so glad to see the EMA added. Theoretically, the FDA is encouraging novel therapies and working to get novel treatments to market quickly but they seem more interested in spouting anti-science and anti-big pharma rhetoric which is defeating all other priorities and leading to mass FDA resignations, leading to chaos and inefficiencies.

0 · Reply

Goodhealth Aug. 22 at 10:06 AM

$LCTX "In addition to testing of other surgical parameters, Genentech currently plans to evaluate two proprietary surgical delivery devices that have potential advantages over available off-the-shelf devices in the GAlette Study." ... chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=320250421&type=PDF&symbol=LCTX&cdn=a10ca407c13d9eb91b3dfb87d6efb722&companyName=Lineage+Cell+Therapeutics%2C+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2026-08-06

1 · Reply

Goodhealth Aug. 22 at 9:11 AM

$LCTX Maybe a sign: Jason Vorhees is the Head of Manufacturing at Genentech’s Cell Therapy site in Hillsboro, Oregon, bringing over 25 years of extensive experience in Biopharmaceutical manufacturing. His career has spanned key leadership roles in Process Development, Manufacturing Science and Technology (MSAT), and Project Management at major industry organizations including Roche/Genentech, Amgen, and Baxter BioScience. Mr. Vorhees is recognized for his commitment to operational excellence, driven by a deep passion for simplification and engineering robust solutions to error-proof challenging manufacturing operations. Cell Therapy Manufacturing and CMC ... https://www.bioprocessingeurope.com/cell-therapy-manufacturing#JasonVorhees

1 · Reply

Market Cap	273.14M
Revenue (ttm)	14.56M
Net Income (ttm)	-63.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-436.33%
Debt to Equity Ratio	0.00

Volume	716,400
Avg Vol	1,446,634
Day's Range	N/A - N/A
Shares Out	252.91M
Stochastic %K	37%
Beta	1.53
Analysts	Strong Sell
Price Target	$5.14